Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
A signature of immune-related gene pairs predicts oncologic outcomes and response to immunotherapy in lung adenocarcinoma
Ist Teil von
Genomics (San Diego, Calif.), 2020-11, Vol.112 (6), p.4675-4683
Ort / Verlag
United States: Elsevier Inc
Erscheinungsjahr
2020
Quelle
Access via ScienceDirect (Elsevier)
Beschreibungen/Notizen
In this study, we established the predictive model for lung adenocarcinoma (LUAD) depending on immune-related gene pairs (IRGPs) signature, which could not consider the technical bias of different platforms. Furthermore, we explored the predictive model with regard to the immune microenvironment and response to immunotherapy and identified specific drugs targeting the IRGPs model. Twenty-three IRGPs were identified and comprised the predictive model. When compared with the high-risk group, the low-risk group displayed a distinctly favorable prognosis and was characterized by increased immune score and decreased tumor purity. In addition, the low-risk group exhibited higher expression of immune checkpoint molecules, lower tumor stemness index, and was much more sensitive to immunotherapy. Lastly, candidate drugs that aimed at LUAD subtype differentiation were identified. The derived IRGPs model is an adverse independent biomarker for estimating oncologic outcomes in LUAD patients, and may be helpful to formulate personalized immunotherapy strategy.
•23 immune-related gene pairs were constructed the prognostic model and shown to be an independent prognostic factor in LUAD.•Tumor immune microenvironment and response to immunotherapy varied in LUAD patients with different risk groups.•Candidate drugs that aimed at LUAD subtype differentiation were identified.